Cost-utility analysis of glucagon-like Peptide-1 agonists compared with dipeptidyl peptidase-4 inhibitors or neutral protamine hagedorn Basal insulin as add-on to metformin in type 2 diabetes in sweden
about
Future challenges and therapeutic opportunities in type 2 diabetes: Changing the paradigm of current therapyNovel Therapeutics for Diabetes: Uptake, Usage Trends, and Comparative Effectiveness.The place of DPP-4 inhibitors in the treatment algorithm of diabetes type 2: a systematic review of cost-effectiveness studies.Cost of severe hypoglycaemia in nine European countries.Achieving Good Glycemic Control Early After Onset of Diabetes: A Cost-Effectiveness Analysis in Patients with Type 1 Diabetes in Sweden.Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes.
P2860
Cost-utility analysis of glucagon-like Peptide-1 agonists compared with dipeptidyl peptidase-4 inhibitors or neutral protamine hagedorn Basal insulin as add-on to metformin in type 2 diabetes in sweden
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Cost-utility analysis of gluca ...... n in type 2 diabetes in sweden
@ast
Cost-utility analysis of gluca ...... n in type 2 diabetes in sweden
@en
Cost-utility analysis of gluca ...... n in type 2 diabetes in sweden
@nl
type
label
Cost-utility analysis of gluca ...... n in type 2 diabetes in sweden
@ast
Cost-utility analysis of gluca ...... n in type 2 diabetes in sweden
@en
Cost-utility analysis of gluca ...... n in type 2 diabetes in sweden
@nl
prefLabel
Cost-utility analysis of gluca ...... n in type 2 diabetes in sweden
@ast
Cost-utility analysis of gluca ...... n in type 2 diabetes in sweden
@en
Cost-utility analysis of gluca ...... n in type 2 diabetes in sweden
@nl
P2860
P50
P921
P1433
P1476
Cost-utility analysis of gluca ...... n in type 2 diabetes in sweden
@en
P2093
Ulf G Gerdtham
P2860
P2888
P304
P356
10.1007/S13300-014-0080-0
P577
2014-09-12T00:00:00Z
P5875
P6179
1016181262